KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2016 - 2020)

Rigel Pharmaceuticals has reported Non-Current Deffered Revenue over the past 11 years, most recently at $146000.0 for Q3 2020.

  • For Q3 2020, Non-Current Deffered Revenue fell 99.42% year-over-year to $146000.0; the TTM value through Sep 2020 reached $146000.0, down 99.42%, while the annual FY2019 figure was $1.4 million, 0.28% changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2020 was $146000.0 at Rigel Pharmaceuticals, down from $1.6 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $26.4 million in Q2 2019 and troughed at $90000.0 in Q4 2017.
  • A 5-year average of $6.3 million and a median of $1.4 million in 2018 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 14720.79% in 2019 and later plummeted 99.42% in 2020.
  • Year by year, Non-Current Deffered Revenue stood at $279000.0 in 2016, then tumbled by 67.74% to $90000.0 in 2017, then skyrocketed by 1464.44% to $1.4 million in 2018, then fell by 0.28% to $1.4 million in 2019, then crashed by 89.6% to $146000.0 in 2020.
  • Business Quant data shows Non-Current Deffered Revenue for RIGL at $146000.0 in Q3 2020, $1.6 million in Q1 2020, and $1.4 million in Q4 2019.